Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

14.37
+1.8414.64%
Post-market: 14.370.00000.00%19:30 EDT
Volume:126.79K
Turnover:1.65M
Market Cap:128.82M
PE:-1.14
High:14.96
Open:12.88
Low:12.26
Close:12.53
52wk High:27.40
52wk Low:6.27
Shares:8.97M
Float Shares:4.39M
Volume Ratio:2.74
T/O Rate:2.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.6200
EPS(LYR):-22.6100
ROE:-172.30%
ROA:-81.06%
PB:2.61
PE(LYR):-0.64

Loading ...

ProMIS Neurosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 01

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

GlobeNewswire
·
Sep 01

ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital

TIPRANKS
·
Aug 21

ProMIS Neurosciences Price Target Raised to $100.00/Share from $69.00 by Guggenheim

Dow Jones
·
Aug 14

Guggenheim Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)

TIPRANKS
·
Aug 14

Annovis Bio Q2 Loss Widens as R&D Costs Rise

Reuters
·
Aug 14

Analysts Are Bullish on These Healthcare Stocks: ProMIS Neurosciences (PMN), Ascendis Pharma (ASND)

TIPRANKS
·
Aug 14

ProMIS Neurosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

ProMIS Neurosciences Q2 Net Loss Widens

Reuters
·
Aug 14

ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate

Benzinga Earnings
·
Aug 14

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

THOMSON REUTERS
·
Aug 14

ProMIS Neurosciences Q2 EPS USD -1.28

THOMSON REUTERS
·
Aug 14

ProMIS Neurosciences Inc Expected to Post a Loss of $1.38 a Share - Earnings Preview

Reuters
·
Aug 11

ProMIS Neurosciences Chief Development Officer Johanne Kaplan Acquires 2,280 Common Shares Worth $30,324

Reuters
·
Aug 08

ProMIS Neurosciences to Report Q2 Results, Host Investor Call and Webcast

Reuters
·
Aug 04

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

GlobeNewswire
·
Aug 04

ProMIS Neurosciences is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 28

Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating

MT Newswires Live
·
Jul 28

ProMIS Neurosciences Inc : Chardan Capital Markets Raises Target Price to $33 from $20

THOMSON REUTERS
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Opko Health (OPK), ProMIS Neurosciences (PMN) and The Ensign Group (ENSG)

TIPRANKS
·
Jul 28